Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells

Authors

  • I. Venza,

    1. Department of Experimental Specialized Medical and Surgical and Odontostomatology Sciences, University of Messina, Messina, Italy
    Search for more papers by this author
    • These authors contributed equally to this work and therefore should be considered equal first authors.
  • M. Visalli,

    1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
    Search for more papers by this author
    • These authors contributed equally to this work and therefore should be considered equal first authors.
  • R. Oteri,

    1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
    Search for more papers by this author
  • M. Cucinotta,

    1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
    Search for more papers by this author
  • D. Teti,

    Corresponding author
    1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
    • Department of Experimental Specialized Medical and Surgical and Odontostomatology Sciences, University of Messina, Messina, Italy
    Search for more papers by this author
  • M. Venza

    1. Department of Experimental Specialized Medical and Surgical and Odontostomatology Sciences, University of Messina, Messina, Italy
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 26, Issue 5, 761, Article first published online: 7 August 2013

CORRESPONDENCE Diana Teti, e-mail: dteti@unime.it

Summary

Here, we explored the effects of the novel class II-specific histone deacetylase inhibitors (HDACis) MC1568 and MC1575 on interleukin-8 (IL-8) expression and cell proliferation in cutaneous melanoma cell line GR-M and uveal melanoma cell line OCM-3 upon stimulation with phorbol 12-myristate 13-acetate (PMA). We found that PMA upregulated IL-8 transcription via the AP-1 binding site and identified c-Jun as the transcription factor involved in this eventS. MC1568 and MC1575 inhibited IL-8 levels and cell proliferation in either unstimulated or PMA-stimulated melanoma cells. They acted by suppressing (i) c-Jun binding to the IL-8 promoter, (ii) recruitment of histones 3 and 4, RNA polymerase II and TFIIB to the c-Jun promoter, and (iii) c-Jun expression. Our findings provide new insights into mechanisms underlying anti-tumoral activities of class II-specific HDACis in human melanoma and suggest that they may constitute a novel therapeutic strategy for improving the treatment of this cancer.

Ancillary